Annals of Pharmacotherapy · 2015 · 39 citations · 15 references
PharmacyPharmacologyToxicologyPharmacovigilanceSubstance Abuse ToxicologySubstance Use DisordersAdverse Effects Of AnalgesicsAnalgesiaDrugs Of AbuseOpioid AnalgesicsOpioid ToxicologyPharmacoepidemiologyClinical Adverse EffectsCohort Study InvestigationPoison Center Data AnalysisPoison Center Data SurveillancePoison Control DataPoison Control SystemsRespiratory Depression RiskRetrospective Case Study
BACKGROUND: Tapentadol (TAP) and tramadol (TRA) provide pain relief through similar monoaminergic and opioid agonist properties. OBJECTIVE: To compare clinical effects and medical outcomes between TAP and TRA exposures reported to the National Poison Data System of the American Association of Poison Control Centers. METHODS: A retrospective cohort study was conducted analyzing national data for single medication TAP or TRA cases reported from June 2009 through December 2011. Case outcomes, dichotomized as severe versus mild; clinical effects; and use of naloxone were compared. RESULTS: There were 217 TAP and 8566 TRA cases. Significantly more severe outcomes were associated with TAP exposures for an all-age comparison (relative risk [RR] = 1.24; 95% CI = 1.04-1.48), and for the <6-year-old age group (RR = 5.76; 95% CI = 2.20-15.11). Patients with TAP exposures had significantly greater risk of respiratory depression (RR = 5.56; 95% CI = 3.50-8.81), coma (RR = 4.16; 95% CI = 2.33-7.42), drowsiness/lethargy (RR = 1.38; 95% CI = 1.15-1.66), slurred speech (RR = 3.51; 95% CI = 1.98-6.23), hallucination/delusion (RR = 7.25; 95% CI = 3.61-14.57), confusion (RR = 2.54; 95% CI = 1.56-4.13) and use of naloxone (RR = 3.80; 95% CI = 2.96-4.88). TRA exposures had significantly greater risk of seizures (RR = 7.94; 95% CI = 2.99-20.91) and vomiting (RR = 1.96; 95% CI = 1.07-3.60). CONCLUSION: TAP was associated with significantly more toxic clinical effects and severe outcomes consistent with an opioid agonist. TRA was associated with significantly higher rates of seizures and vomiting.
15
Prospective Multicenter Evaluation of Tramadol Exposure
Henry A. Spiller, Susan E. Gorman, Danny Villalobos et al. · Journal of Toxicology Clinical Toxicology · 1997 · 194 citations
Pharmacy, Pharmacology, Toxicology +17